Praxis Precision Medicines, Inc. Stock Price, News & Analysis

Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation in three major investor conferences in November 2024. The company will present at the Truist Securities BioPharma Symposium in New York on November 7 at 9:40am ET, the Guggenheim Securities Inaugural Healthcare Innovation Conference in Boston on November 11 at 1:00pm ET, and the Jefferies London Healthcare Conference in London on November 20-21.

Management will participate in fireside chats at both Truist and Guggenheim events, with the Guggenheim session being available via live webcast. One-on-one meetings will be available at all three conferences. The Guggenheim webcast will be accessible through the company's website for 90 days after the event.

Praxis Precision Medicines reported Q3 2024 financial results and provided corporate updates. The company maintains cash runway into 2027 with $411.2 million in cash and equivalents. Key highlights include planned interim analysis for ulixacaltamide's Essential3 Phase 3 program in Q1 2025, positive topline results from EMBOLD cohort 1 showing 46% placebo-adjusted reduction in monthly motor seizures, and advancement of vormatrigine trials. Q3 financial results showed a net loss of $51.9 million, with R&D expenses at $41.9 million and G&A expenses at $15.3 million. The company recognized $0.3 million in collaboration revenue.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, announced it will release its Q3 2024 financial results on Wednesday, November 6, 2024, before market open. The company will host a live webcast at 8am ET on the same day. Investors can access the webcast through a registration link or the company's website. A replay will be available for 90 days on the company's website.

Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation in the Movement Disorders Society (MDS) 2024 International Congress in Philadelphia, Pennsylvania, from September 27 to October 1, 2024. The company will present a poster and platform talk showcasing its Phase 3 clinical program for ulixacaltamide, a potential therapy for adults with essential tremor (ET).

The presentations will focus on the Essential3 program, an innovative multi-study Phase 3 initiative evaluating the efficacy and safety of ulixacaltamide. Praxis will be available at booth #1008 and will deliver a platform presentation on September 28 and a poster presentation on September 29. Presentation materials will be made available on the company's website following the conference.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focusing on central nervous system (CNS) disorders, has announced its participation in two upcoming investor conferences. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 12:00pm EDT in New York, NY. Additionally, Praxis will attend the Baird Global Healthcare Conference on September 11, 2024, at 2:35pm EDT, also in New York, NY.

Both presentations will be in a fireside chat format. The company will be available for one-on-one meetings with interested investors during these conferences. A replay of the presentations will be available on Praxis' website for 90 days after the events.

Praxis Precision Medicines (NASDAQ: PRAX) will present preclinical and clinical data from three epilepsy programs at the International League Against Epilepsy 15th European Epilepsy Congress in Rome, Italy, from September 7-11, 2024. The company will showcase six presentations, including an oral presentation on significant seizure reduction in pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy treated with elsunersen. Poster presentations will cover topics such as:

• Pharmacokinetics and safety of PRAX-628 for focal onset seizures
• A first-in-patient report of elsunersen in a preterm infant
• The EMBOLD clinical trial of PRAX-562
• Novel translational and EEG methods for epilepsy drug development

Praxis is currently enrolling registrational trials for elsunersen and relutrigine, with plans to initiate the ENERGY program for PRAX-628 this year.

Praxis Precision Medicines (NASDAQ: PRAX) has announced positive topline results from the EMBOLD study evaluating relutrigine in SCN2A and SCN8A developmental epilepsies. Key findings include:

- 46% placebo-adjusted monthly motor seizure reduction
- Over 30% of patients achieved seizure freedom
- Meaningful gains in alertness, communication, and seizure severity
- 75% reduction in median seizure rate in long-term extension

The company has initiated the registrational phase of the EMBOLD study for SCN2A and 8A. These results suggest relutrigine's potential to significantly impact treatment for pediatric epilepsy, offering hope for patients and families affected by these rare genetic disorders.

Praxis Precision Medicines (NASDAQ: PRAX) has announced that it will release topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) on September 3, 2024, before the market opens. The study focuses on SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs). Following the announcement, the company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results. This event is significant for Praxis, a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

Praxis Precision Medicines (NASDAQ: PRAX) provided a corporate update and reported Q2 2024 financial results. Key highlights include:

• Up to four programs in registrational phase by 2025
• Planned interim analysis for ulixacaltamide Essential3 Study 1 in Q4 2024
• Topline results for Phase 2 EMBOLD study of relutrigine expected in Q3 2024
• PRAX-628 Phase 2/3 POWER1 study to initiate in Q4 2024
• Cash and investments of $434 million as of June 30, 2024, maintaining runway into 2027

Financial results show $0.4 million in collaboration revenue, $27.3 million in R&D expenses, and a net loss of $32.7 million for Q2 2024. The company's strong cash position supports advancement of its clinical programs towards regulatory registrations.